Check Claims Before You Publish

High-level synthesis (evidence-weighted)

1. Domain and focus: Bastani's corpus centers on women's health—urogynecology (pelvic-organ prolapse, pelvic-floor rehab, urinary incontinence), obstetrics (cesarean techniques, induction), and probiotics/gynecologic infections — supported by her top-cited works in bacterial vaginosis and pelvic-floor trials Probiotics & BV Review (2013)Pelvic-floor RCT (2019)
2. Impact metrics: Provided metrics (h-index ~12–13, total citations ~636–695, works ~57–62) place Bastani at established national/regional prominence with several field-relevant, moderately-influential papers; impact is driven by a few highly-cited reviews and RCTs rather than many high-impact basic-science discoveries (OpenAlex summary counts_by_year were used for the visualized time-series).
3. Study types & methodology: Portfolio mixes RCTs, randomized clinical trials, cross-sectional epidemiology, surgical outcome comparisons, and systematic reviews/meta-analyses. This breadth indicates methodologic versatility; RCTs and systematic reviews strengthen evidence contribution, but many clinical trials appear single-center, region-specific, and some trials have modest sample sizes—caveats for external validity.
4. Reproducibility & transparency: Several RCTs and systematic reviews were published in established clinical journals (International Urogynecology Journal, BMC Pregnancy and Childbirth, Int J Gynecol Obstet), increasing peer-reviewed transparency; open-access availability differs by paper (some OA, some closed), which constrains independent re-analysis for non-open works Low fetal fraction SR/MA (2022)

Strengths

• Consistent clinical focus with multiple randomized trials and systematic reviews, which are higher on the evidence pyramid than case reports.
• Several well-cited review/trial papers indicate influence in gynecology/urogynecology practice and guidelines.
• Interdisciplinary scope (obstetrics, urogynecology, probiotics) shows broad clinical research competency.

Weaknesses / Blindspots

• Many clinical trials appear single-center and region-specific—potential limits to external validity and generalizability.
• Several topics rely on heterogeneous interventions (e.g., probiotic strains/doses), which complicates pooled inference from reviews.
• Relatively few basic-science or mechanistic papers; influence is clinical rather than foundational biological discovery.

Key uncertainties and what would disprove current assessment

• Large, multi-center RCTs with negative results in her main clinical topics would reduce her apparent clinical influence; conversely, large confirmatory multicenter trials would increase it.
• Evidence of data irregularities or undisclosed conflicts of interest in high-cited works would undermine trust (no such evidence presented in the source materials).

Representative, directly cited works used in this review

1. Probiotics & BV Review (2013)
2. Pelvic-floor RCT (2019)
3. Low fetal fraction SR/MA (2022)
4. Impacted-fetal-head methods (2012)

Actionable suggestions to strengthen scientific profile

• Pursue multicenter, adequately-powered confirmatory RCTs (pre-registered) in highest-impact clinical questions (pelvic-floor rehab, probiotic interventions) to shift evidence from moderate to strong.
• Harmonize intervention definitions (e.g., probiotic strain/dose) to reduce heterogeneity in reviews and enable meta-analytic pooling with lower risk of confounding.
• Prioritize open-data and protocol pre-registration to increase reproducibility and citation reliability.